RU2232769C2 - Замещенные желчными кислотами фенилалкеноилгуанидины, лекарственное средство - Google Patents

Замещенные желчными кислотами фенилалкеноилгуанидины, лекарственное средство Download PDF

Info

Publication number
RU2232769C2
RU2232769C2 RU2001114207/04A RU2001114207A RU2232769C2 RU 2232769 C2 RU2232769 C2 RU 2232769C2 RU 2001114207/04 A RU2001114207/04 A RU 2001114207/04A RU 2001114207 A RU2001114207 A RU 2001114207A RU 2232769 C2 RU2232769 C2 RU 2232769C2
Authority
RU
Russia
Prior art keywords
alkyl
acid
hydrogen
compounds
substituted
Prior art date
Application number
RU2001114207/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2001114207A (ru
Inventor
Андреас ВАЙХЕРТ (DE)
Андреас Вайхерт
Альфонс ЭНХСЕН (DE)
Альфонс ЭНХСЕН
Ойген ФАЛЬК (DE)
Ойген Фальк
Ханс-Вилли ЯНСЕН (DE)
Ханс-Вилли ЯНСЕН
Вернер КРАМЕР (DE)
Вернер Крамер
Ян-Роберт ШВАРК (DE)
Ян-Роберт Шварк
Ханс Йохен ЛАНГ (DE)
Ханс Йохен Ланг
Original Assignee
Авентис Фарма Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фарма Дойчланд Гмбх filed Critical Авентис Фарма Дойчланд Гмбх
Publication of RU2001114207A publication Critical patent/RU2001114207A/ru
Application granted granted Critical
Publication of RU2232769C2 publication Critical patent/RU2232769C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2001114207/04A 1998-10-28 1999-10-15 Замещенные желчными кислотами фенилалкеноилгуанидины, лекарственное средство RU2232769C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19849722A DE19849722A1 (de) 1998-10-28 1998-10-28 Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19849722.9 1998-10-28

Publications (2)

Publication Number Publication Date
RU2001114207A RU2001114207A (ru) 2003-06-27
RU2232769C2 true RU2232769C2 (ru) 2004-07-20

Family

ID=7885948

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001114207/04A RU2232769C2 (ru) 1998-10-28 1999-10-15 Замещенные желчными кислотами фенилалкеноилгуанидины, лекарственное средство

Country Status (22)

Country Link
US (1) US6166002A (https=)
EP (1) EP1124841B1 (https=)
JP (1) JP4616479B2 (https=)
KR (1) KR20010085973A (https=)
CN (1) CN1325403A (https=)
AT (1) ATE236191T1 (https=)
AU (1) AU757365B2 (https=)
BR (1) BR9914929A (https=)
CA (1) CA2349523A1 (https=)
CZ (1) CZ20011429A3 (https=)
DE (2) DE19849722A1 (https=)
DK (1) DK1124841T3 (https=)
ES (1) ES2191466T3 (https=)
HK (1) HK1041271A1 (https=)
HU (1) HUP0103751A3 (https=)
ID (1) ID29025A (https=)
PL (1) PL348108A1 (https=)
PT (1) PT1124841E (https=)
RU (1) RU2232769C2 (https=)
TR (1) TR200101163T2 (https=)
WO (1) WO2000024761A1 (https=)
ZA (1) ZA200103106B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19941764A1 (de) 1999-09-02 2001-03-15 Aventis Pharma Gmbh Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente
EP2617709B8 (en) 2003-06-26 2022-12-21 Biotron Limited Guanidine derivatives as antiviral agents
DE10338554A1 (de) * 2003-08-22 2005-03-31 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US20050171215A1 (en) * 2004-01-30 2005-08-04 Ethicon, Inc. Germicidal compositions containing halogenated phthalaldehyes, and methods of using such compositions for disinfection or sterilization
US6891069B1 (en) 2004-01-30 2005-05-10 Ethicon, Inc. Synthesis of 4-substituted phthalaldehyde
US7476767B2 (en) 2004-01-30 2009-01-13 Ethicon, Inc. Alpha-hydroxy sulfonate aldehydes, germicidal compositions containing the alpha-hydroxy sulfonate aldehydes, or mixtures of alpha-hydroxy sulfonate aldehydes and phthalaldehydes, and methods of using the compounds or compositions for disinfection or sterilization
US7390837B2 (en) 2004-01-30 2008-06-24 Ethicon, Inc. Germicidal compositions containing phenylmalonaldehyde-type compounds, or mixtures of phenylmalonaldehyde-type compounds and phthalaldehydes, and methods of using such compositions for disinfection or sterilization
US7291649B2 (en) 2005-06-29 2007-11-06 Ethicon, Inc. Forming germicidal aromatic dialdehydes with acetals
CZ301037B6 (cs) * 2007-09-06 2009-10-21 Vysoká škola chemicko-technologická v Praze Amidové konjugáty steroidních a žlucových kyselin s D-glukosaminem a zpusob jejich prípravy
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
LT2983667T (lt) 2013-04-12 2019-07-10 Ardelyx, Inc. Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
WO2020117945A1 (en) 2018-12-04 2020-06-11 President And Fellows Of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
AU2020274319B2 (en) 2019-05-10 2026-02-12 President And Fellows Of Harvard College Small molecule modulators of gut bacterial bile acid metabolism
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289021B (https=) * 1993-05-08 1996-10-21 Hoechst Ag
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
JPH0959162A (ja) * 1995-08-28 1997-03-04 Makoto Takahashi 胆石溶解剤
DE19633966A1 (de) * 1996-08-22 1998-02-26 Hoechst Ag Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
JP2002528460A (ja) 2002-09-03
CA2349523A1 (en) 2000-05-04
KR20010085973A (ko) 2001-09-07
AU6203299A (en) 2000-05-15
HUP0103751A2 (hu) 2002-04-29
EP1124841A1 (de) 2001-08-22
DK1124841T3 (da) 2003-07-28
DE59904875D1 (de) 2003-05-08
CN1325403A (zh) 2001-12-05
PL348108A1 (en) 2002-05-06
JP4616479B2 (ja) 2011-01-19
ZA200103106B (en) 2002-08-28
DE19849722A1 (de) 2000-05-04
AU757365B2 (en) 2003-02-20
TR200101163T2 (tr) 2001-08-21
ID29025A (id) 2001-07-26
EP1124841B1 (de) 2003-04-02
WO2000024761A1 (de) 2000-05-04
PT1124841E (pt) 2003-08-29
HK1041271A1 (zh) 2002-07-05
CZ20011429A3 (cs) 2001-08-15
US6166002A (en) 2000-12-26
BR9914929A (pt) 2001-07-10
ATE236191T1 (de) 2003-04-15
HUP0103751A3 (en) 2002-12-28
ES2191466T3 (es) 2003-09-01

Similar Documents

Publication Publication Date Title
RU2232769C2 (ru) Замещенные желчными кислотами фенилалкеноилгуанидины, лекарственное средство
JPH0747536B2 (ja) 破骨細胞の骨吸収活性の抑制用医薬組成物
JP2724114B2 (ja) トリテルペン誘導体およびそれを含有するエンドセリンレセプター拮抗剤
JP4768941B2 (ja) 胆汁酸置換フェニルアルケノイルグアニジン、それらの製造方法、医薬または診断薬としてのそれらの使用、およびそれらを含む医薬
RU2247125C2 (ru) Конъюгаты 4-бензиламинохинолинов с желчной кислотой и их гетероаналоги, способ их получения и лекарственные средства на основе этих соединений
JPH07119230B2 (ja) 骨吸収阻害剤としてのビスホスホン酸類のアシルオキシメチルエステル
EP0341961A2 (en) Polymalonic acids as boneaffinity agents
MXPA01004147A (en) Bile-acid substituted phenyl alkenoyl guanidines, method for the production thereof, use thereof as medicaments or diagnostic agents and medicaments that contain them
JPH06505735A (ja) 新規なスルホンアミド、その製造方法およびこれらの化合物を含む医薬組成物
DE19945385A1 (de) Substituierte 4-Benzylaminochinoline und ihre Heteroanlagen, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
JPWO1998011124A1 (ja) 3−置換−d−ホモ−1,3,5,(10)−エストラトリエン誘導体
DE10028193A1 (de) Substituierte 4-Benzylamminochinoline und ihre Heteroanalogen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika, sowie sie enthaltende Medikamente

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20061016